MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 15, 2008; DOI: 10.1124/mol.108.049783


This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.108.049783v1
mol.108.049783v3
74/5/1308    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Gonzalez-Cabrera, P. J
Right arrow Articles by Rosen, H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gonzalez-Cabrera, P. J
Right arrow Articles by Rosen, H.


Received for publication June 20, 2008.
Revised August 15, 2008.
Accepted for publication August 15, 2008.

Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like head-group interactions

Pedro J Gonzalez-Cabrera 1, Euijung Jo 1, M Germana Sanna 1, Steven Brown 1, Nora Leaf 1, David Marsolais 1, Marie-Therese Schaeffer 1, Jackie Chapman 1, Michael Cameron 2, Miguel Guerrero 1, Edward Roberts 1, Hugh Rosen 1*

1 The Scripps Research Institute 2 Translational Research Institute, Scripps Florida

* Address correspondence to: E-mail: hrosen{at}scripps.edu

Abstract

Strong evidence exists for interactions of zwitterionic phosphate and amine groups in Sphingosine-1 phosphate (S1P) to conserved R and E residues present at the extracellular face of transmembrane-3 (TM3) of S1P receptors. The contribution of R120 and E121 for high affinity ligand-receptor interactions is essential, as single-point R120A or 121A S1P1 mutants neither bind S1P nor transduce S1P function. Because S1P receptors are therapeutically interesting, identifying potent selective agonists with different binding modes and in vivo efficacy is of pharmacological importance. Here we describe a modestly water-soluble highly-selective S1P1 agonist (CYM-5442) that does not require R120 or E121 residues for activating S1P1-dependent p42/p44 MAPK phosphorylation, which defines a new hydrophobic pocket in S1P1. CYM-5442 is a full agonist in vitro for S1P1 internalization, phosphorylation and ubiquitination. Importantly, CYM-5442 was a full agonist for induction and maintenance of S1P1-dependent lymphopenia, decreasing B-lymphocytes by 65% and T-lymphocytes by 85% of vehicle. Induction of CYM-5442 lymphopenia was dose and time-dependent, requiring serum concentrations in the 50 nM range. In vitro measures of S1P1 activation by CYM-5442 were non-competitively inhibited by a specific S1P1 antagonist (W146), competitive for S1P, FTY720-P and SEW2871. In addition, lymphopenia by CYM-5442 was reversed by W146 administration or upon pharmacokinetic agonist clearance. Pharmacokinetics in mice also indicated that CYM-5442 partitions significantly in central nervous tissue. These data show that CYM-5442 activates S1P1-dependent pathways in vitro and to levels of full efficacy in vivo through a hydrophobic pocket, separable from the orthosteric site of S1P binding that is headgroup dependent.


Key words: Gi family, Sphingolipids, Sequestration/Internalization, Func. analysis receptor/ion channel mutants, Angiogenesis





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics